# Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa

> **NCT00498056** · PHASE2 · WITHDRAWN · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)**

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** VRC-HIVDNA016-00-VP
- **BIOLOGICAL:** VRC-HIVADV014-00-VP
- **BIOLOGICAL:** VRC-HIVDNA016-00-VP placebo
- **BIOLOGICAL:** VRC-HIVADV014-00-VP placebo

## Key facts

- **NCT ID:** NCT00498056
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2021-11-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00498056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00498056, "Safety and Effectiveness of an HIV DNA Vaccine Followed by an HIV Adenoviral Vector Vaccine for Prevention of HIV Infection in the Americas and Africa". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00498056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*